We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IMP:JSEImpala Platinum Holdings Limited Analysis

Data as of 2026-03-11 - not real-time

ZAC 27,781.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Impala Platinum is trading well below its 20‑day (29,423) and 50‑day (30,001) moving averages, with a bearish MACD histogram and a neutral RSI around 45, indicating short‑term weakness despite a neutral longer‑term trend. However, the DCF fair value of ~46,483 suggests an upside of roughly 34%, and the forward PE of 9.7 points to a dramatic earnings rebound (forward EPS 28.66 vs trailing 0.83). Recent news of a potential 400% profit jump and analyst upgrades adds momentum, while an increasing volume trend supports growing investor interest. The stock offers a 2.07% dividend yield backed by strong cash flow and low debt, making the payout sustainable.
Given the high 30‑day volatility (~95%) but low beta (~0.47), price swings are pronounced yet not strongly correlated with broader market moves. Geographic exposure to South Africa, Zimbabwe and Canada introduces moderate regulatory and political risk, while liquidity remains adequate with solid market cap and volume. Overall, the valuation leans undervalued with a growth tilt, suggesting opportunities for patient investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent profit surge and analyst upgrades
  • Bearish short‑term technical indicators
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant upside to DCF fair value
  • Forward earnings expansion (forward PE 9.7)
  • Increasing trading volume indicating growing interest

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained demand for platinum group metals
  • Strong balance sheet with ample cash and low debt
  • Sustainable dividend yield supporting total return

Key Metrics & Analysis

Financial Health

Revenue Growth43.70%
Profit Margin7.90%
P/E Ratio334.7
ROE8.28%
ROA5.87%
Debt/Equity2.95
P/B Ratio257.1
Op. Cash FlowZAC13.5B
Free Cash FlowZAC10.6B

Technical Analysis

TrendNeutral
RSI45.1
SupportZAC 25,036.00
ResistanceZAC 36,514.00
MA 20ZAC 29,423.85
MA 50ZAC 30,001.20
MA 200ZAC 21,523.66
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Fair ValueZAC 46,483.37
Target PriceZAC 37,202.13
Upside/Downside33.91%
GradeUndervalued
TypeGrowth
Dividend Yield2.07%

Risk Assessment

Beta0.47
Volatility95.08%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.